NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

CompletedN/A

Sponsor: AstraZeneca

Conditions: Biliary Tract Cancer

Countries: Japan

To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with curatively unresectable biliary tract cancer who receive IMFINZI for the first time in combination with gemcitabine hydrochloride and cisplatin.

Exclusion Criteria:

\-

Locations (24)

Aichi, Japan
Aomori, Japan
Chiba, Japan
Ehime, Japan
Fukushima, Japan
Hokkaido, Japan
Hyōgo, Japan
Kagawa, Japan
Kanagawa, Japan
Kyoto, Japan
Miyagi, Japan
Nagano, Japan
Nagasaki, Japan
Nara, Japan
Numakunai, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shiga, Japan
Shimane, Japan
Shizuoka, Japan
Tochigi, Japan
Tokyo, Japan
Yamaguchi, Japan